Literature DB >> 30383414

Lipid mediators of liver injury in nonalcoholic fatty liver disease.

Suthat Liangpunsakul1,2,3, Naga Chalasani1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathological phenotypes ranging from simple steatosis to more severe liver disease associated with cell injury, including nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. Only a subset of patients with NAFLD develop NASH from yet incompletely understood mechanisms. Emerging data suggest lipid species other than triglycerides as contributors to the pathogenesis of NASH. In this mini review, we focus on the recent data on the mechanisms of NASH, focusing on these lipid mediators and their potential as therapeutic targets in NASH.

Entities:  

Keywords:  cell death; inflammation; lipotoxicity; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2018        PMID: 30383414      PMCID: PMC6383373          DOI: 10.1152/ajpgi.00170.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  68 in total

Review 1.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

Authors:  Jay D Horton; Joseph L Goldstein; Michael S Brown
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

2.  Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood.

Authors:  Eric Soupene; Mark S Borja; Mauricio Borda; Sandra K Larkin; Frans A Kuypers
Journal:  Exp Biol Med (Maywood)       Date:  2016-06-27

3.  Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids.

Authors:  Bianca M Arendt; Elena M Comelli; David W L Ma; Wendy Lou; Anastasia Teterina; TaeHyung Kim; Scott K Fung; David K H Wong; Ian McGilvray; Sandra E Fischer; Johane P Allard
Journal:  Hepatology       Date:  2015-02-27       Impact factor: 17.425

4.  Novel association of TM6SF2 rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns.

Authors:  Daniel Seung Kim; Anne U Jackson; Yatong K Li; Heather M Stringham; Johanna Kuusisto; Antti J Kangas; Pasi Soininen; Mika Ala-Korpela; Charles F Burant; Veikko Salomaa; Michael Boehnke; Markku Laakso; Elizabeth K Speliotes
Journal:  J Lipid Res       Date:  2017-05-24       Impact factor: 5.922

5.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

Authors:  Kerry L Donnelly; Coleman I Smith; Sarah J Schwarzenberg; Jose Jessurun; Mark D Boldt; Elizabeth J Parks
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

6.  Obesity-induced CerS6-dependent C16:0 ceramide production promotes weight gain and glucose intolerance.

Authors:  Sarah M Turpin; Hayley T Nicholls; Diana M Willmes; Arnaud Mourier; Susanne Brodesser; Claudia M Wunderlich; Jan Mauer; Elaine Xu; Philipp Hammerschmidt; Hella S Brönneke; Aleksandra Trifunovic; Giuseppe LoSasso; F Thomas Wunderlich; Jan-Wilhelm Kornfeld; Matthias Blüher; Martin Krönke; Jens C Brüning
Journal:  Cell Metab       Date:  2014-10-07       Impact factor: 27.287

7.  Gastric bypass surgery reduces plasma ceramide subspecies and improves insulin sensitivity in severely obese patients.

Authors:  Hazel Huang; Takhar Kasumov; Patrick Gatmaitan; Helen M Heneghan; Sangeeta R Kashyap; Philip R Schauer; Stacy A Brethauer; John P Kirwan
Journal:  Obesity (Silver Spring)       Date:  2011-05-05       Impact factor: 5.002

8.  Statin use and non-alcoholic steatohepatitis in at risk individuals.

Authors:  Paola Dongiovanni; Salvatore Petta; Ville Mannisto; Rosellina Margherita Mancina; Rosaria Pipitone; Vesa Karja; Marco Maggioni; Pirjo Kakela; Olov Wiklund; Enrico Mozzi; Stefania Grimaudo; Dorota Kaminska; Raffaela Rametta; Antonio Craxi; Silvia Fargion; Valerio Nobili; Stefano Romeo; Jussi Pihlajamaki; Luca Valenti
Journal:  J Hepatol       Date:  2015-05-14       Impact factor: 25.083

9.  Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.

Authors:  Puneet Puri; Faridoddin Mirshahi; Onpan Cheung; Ramesh Natarajan; James W Maher; John M Kellum; Arun J Sanyal
Journal:  Gastroenterology       Date:  2007-10-26       Impact factor: 22.682

10.  Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model.

Authors:  D Lee Gorden; Pavlina T Ivanova; David S Myers; J Oliver McIntyre; Michael N VanSaun; J Kelly Wright; Lynn M Matrisian; H Alex Brown
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

View more
  12 in total

Review 1.  Hepatic Steatosis in the Pediatric Population: An Overview of Pathophysiology, Genetics, and Diagnostic Workup.

Authors:  Claudia Phen; Charina M Ramirez
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-04-13

Review 2.  Long noncoding RNA H19 - a new player in the pathogenesis of liver diseases.

Authors:  Zhihong Yang; Ting Zhang; Sen Han; Praveen Kusumanchi; Nazmul Huda; Yanchao Jiang; Suthat Liangpunsakul
Journal:  Transl Res       Date:  2020-11-20       Impact factor: 10.171

3.  TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population.

Authors:  Qun Liu; Feng Xue; Jing Meng; Shou-Sheng Liu; Li-Zhen Chen; Hui Gao; Ning Geng; Wen-Wen Jin; Yong-Ning Xin; Shi-Ying Xuan
Journal:  Lipids Health Dis       Date:  2019-03-09       Impact factor: 3.876

Review 4.  How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease?

Authors:  Yana Geng; Klaas Nico Faber; Vincent E de Meijer; Hans Blokzijl; Han Moshage
Journal:  Hepatol Int       Date:  2021-02-06       Impact factor: 6.047

Review 5.  Mitochondrial Mutations and Genetic Factors Determining NAFLD Risk.

Authors:  Siarhei A Dabravolski; Evgeny E Bezsonov; Mirza S Baig; Tatyana V Popkova; Ludmila V Nedosugova; Antonina V Starodubova; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

6.  Considerations When Choosing High-Fat, High-Fructose, and High-Cholesterol Diets to Induce Experimental Nonalcoholic Fatty Liver Disease in Laboratory Animal Models.

Authors:  Sridhar Radhakrishnan; Steven F Yeung; Jia-Yu Ke; Maísa M Antunes; Michael A Pellizzon
Journal:  Curr Dev Nutr       Date:  2021-11-13

7.  Monoacylglycerol Acyltransferase 1 Knockdown Exacerbates Hepatic Ischemia/Reperfusion Injury in Mice With Hepatic Steatosis.

Authors:  Kim H H Liss; Shelby E Ek; Andrew J Lutkewitte; Terri A Pietka; Mai He; Priya Skaria; Eric Tycksen; Daniel Ferguson; Valerie Blanc; Mark J Graham; Angela M Hall; Mitchell R McGill; Kyle S McCommis; Brian N Finck
Journal:  Liver Transpl       Date:  2020-10-22       Impact factor: 5.799

Review 8.  Epidemiology of Alcohol-Associated Liver Disease.

Authors:  Sen Han; Zhihong Yang; Ting Zhang; Jing Ma; Kristina Chandler; Suthat Liangpunsakul
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

9.  Rapamycin-Loaded mPEG-PLGA Nanoparticles Ameliorate Hepatic Steatosis and Liver Injury in Non-alcoholic Fatty Liver Disease.

Authors:  Ruifang Zhao; Meilin Zhu; Shuang Zhou; Weiyue Feng; Hanqing Chen
Journal:  Front Chem       Date:  2020-05-28       Impact factor: 5.221

10.  Orotic acid-treated hepatocellular carcinoma cells resist steatosis by modification of fatty acid metabolism.

Authors:  Johanna Matilainen; Anne-Mari Mustonen; Kirsi Rilla; Reijo Käkelä; Sanna P Sihvo; Petteri Nieminen
Journal:  Lipids Health Dis       Date:  2020-04-13       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.